{
    "PMC8668943_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjusting for": "birthweight and FCGR2C genotypes",
                        "Fc\u03b3RIIc copy number": "1 copy",
                        "statistical representation": "Univariate OR (95% CI)"
                    },
                    "measures": "[Univariate OR, P-value]",
                    "outcomes": "[0.29 (0.12-0.71), 0.007]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "1 copy",
                        "Bonferroni corrected P-value": "0.112"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.29, (0.12-0.71), 0.007]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjusting for": "birthweight and FCGR2C genotypes",
                        "Fc\u03b3RIIc copy number": "1 copy",
                        "statistical representation": "Adjusted OR"
                    },
                    "measures": "[Adjusted OR, P-value]",
                    "outcomes": "[0.37 (0.15-0.90), 0.029]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "1 copy",
                        "Bonferroni corrected P-value": "0.464"
                    },
                    "measures": "[Adjusted OR, 95%CI, P-value]",
                    "outcomes": "[0.37 (0.15-0.90), 0.029]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjusting for": "birthweight and FCGR2C genotypes",
                        "Fc\u03b3RIIc copy number": "2 copies",
                        "statistical representation": "Univariate OR (95% CI)"
                    },
                    "measures": "[Univariate OR]",
                    "outcomes": "[Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "2 copies",
                        "statistical measure": "Adjusted OR",
                        "value": "Ref"
                    }
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjusting for": "birthweight and FCGR2C genotypes",
                        "Fc\u03b3RIIc copy number": "2 copies",
                        "statistical representation": "Adjusted OR"
                    },
                    "measures": "[Adjusted OR]",
                    "outcomes": "[Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.99, (0.63-1.57), 0.978]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjusting for": "birthweight and FCGR2C genotypes",
                        "Fc\u03b3RIIc copy number": "2 copies",
                        "statistical representation": "Adjusted OR"
                    },
                    "measures": "[Adjusted OR]",
                    "outcomes": "[Ref]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Adjusted OR, 95% CI, P-value]",
                    "outcomes": "[0.74, (0.43-1.27), 0.275]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjusting for": "birthweight and FCGR2C genotypes",
                        "Fc\u03b3RIIc copy number": "\u22653 copies",
                        "statistical representation": "Univariate OR (95% CI)"
                    },
                    "measures": "[Univariate OR, P-value]",
                    "outcomes": "[0.99 (0.63-1.57), 0.978]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Univariate OR, 95% CI, P-value]",
                    "outcomes": "[0.99, (0.63-1.57), 0.978]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjusting for": "birthweight and FCGR2C genotypes",
                        "Fc\u03b3RIIc copy number": "\u22653 copies",
                        "statistical representation": "Adjusted OR"
                    },
                    "measures": "[Adjusted OR, P-value]",
                    "outcomes": "[0.74 (0.43-1.27), 0.275]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of FCGR2C CNR1 copy number distribution on perinatal HIV-1 acquisition",
                        "adjustment factors": "birthweight and FCGR2C genotypes",
                        "group": "Total group",
                        "Fc\u03b3RIIc copy number": "\u22653 copies"
                    },
                    "measures": "[Adjusted OR, 95% CI, P-value]",
                    "outcomes": "[0.74, (0.43-1.27), 0.275]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 6,
        "total_ground_truth_claims": 5,
        "number_of_matches": 5
    },
    "PMC5817808_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "mode of feeding": "Exclusive replacement feeding",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.35 [0.52-3.49]",
                        "0.54"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "mode of feeding": "Exclusive replacement feeding",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "mode of feeding": "Exclusive replacement feeding",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "HIV- Status": "Negative",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.35 [0.52-3.49]",
                        "0.54"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "HIV- Status": "Negative",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "HIV- Status": "Negative",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "HIV- Status": "Negative",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.04-2.42]",
                        "0.26"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "HIV- Status": "Negative",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "HIV- Status": "Negative",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "HIV- Status": "Negative",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.30 [0.08-1.11]",
                        "0.071"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "HIV- Status": "Negative",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.35 [0.52-3.49]",
                        "0.54"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.04-2.42]",
                        "0.26"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.30 [0.08-1.11]",
                        "0.071"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.70 [0.16-2.96]",
                        "0.63"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.93 [0.21-4.12]",
                        "0.92"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "birth weight": "<2500 g",
                        "unadjusted HR": "Ref",
                        "unadjusted p-value": "Ref",
                        "adjusted HR": "Ref",
                        "adjusted p-value": "Ref"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.35 [0.52-3.49]",
                        "0.54"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive breast feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "1.16 [0.44-3.08]",
                        "0.76"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Exclusive replacement feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.04-2.42]",
                        "0.26"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "mode of feeding": "Mixed feeding"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.44 [0.053-3.74]",
                        "0.45"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.31 [0.11-0.90]",
                        "0.032"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Positive"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.30 [0.08-1.11]",
                        "0.071"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "HIV Status": "Negative"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Unadjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.70 [0.16-2.96]",
                        "0.63"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": ">= 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "0.93 [0.21-4.12]",
                        "0.92"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program",
                        "Birth weight": "< 2500 g"
                    },
                    "measures": [
                        "Adjusted Hazard Ratio",
                        "p-value"
                    ],
                    "outcomes": [
                        "Ref",
                        "Ref"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "Essos hospital center PMTCT program",
                        "analysis": "survival at 24 months",
                        "population": "HIV exposed infants",
                        "test": "Global Schoenfeld residuals test",
                        "p-value": "0.23"
                    },
                    "measures": "[]",
                    "outcomes": "[0.23]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Global Schoenfeld residuals test",
                        "population": "HIV exposed infants",
                        "program": "Essos hospital center PMTCT program"
                    },
                    "measures": [
                        "p-value"
                    ],
                    "outcomes": [
                        "0.23"
                    ]
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 4,
        "total_ground_truth_claims": 15,
        "number_of_matches": 4
    },
    "PMC5574138_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "meta-regression",
                        "covariate": "Length of follow-up",
                        "statistical representation": "95% confidence interval"
                    },
                    "measures": "[estimate, standard error, 95% confidence interval]",
                    "outcomes": "[-0.0138, 0.0666, (-0.1322, 0.1046)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Length of follow-up",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[-0.0138, 0.0666, (-0.1322\u20130.1046)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "meta-regression",
                        "covariate": "Median CD4 count",
                        "statistical representation": "95% confidence interval"
                    },
                    "measures": "[estimate, standard error, 95% confidence interval]",
                    "outcomes": "[-0.0034, 0.0066, (-0.0150, 0.0079)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Median CD4 count",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[-0.0034, 0.0066, (-0.0150\u20130.0079)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "meta-regression",
                        "covariate": "Median age",
                        "statistical representation": "95% confidence interval"
                    },
                    "measures": "[estimate, standard error, 95% confidence interval]",
                    "outcomes": "[0.0415, 0.0503, (-0.1013, 0.0755)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Median age",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[0.0415, 0.0503, (-0.1013\u20130.0755)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "meta-regression",
                        "covariate": "Year of publication",
                        "statistical representation": "95% confidence interval"
                    },
                    "measures": "[estimate, standard error, 95% confidence interval]",
                    "outcomes": "[0.0637, 0.0815, (-0.1736, 0.0980)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Year of publication",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[0.0637, 0.0815, (-0.1736\u20130.0980)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "meta-regression",
                        "covariate": "Female proportion",
                        "statistical representation": "95% confidence interval"
                    },
                    "measures": "[estimate, standard error, 95% confidence interval]",
                    "outcomes": "[-0.5305, 1.4575, (-3.6792, 2.6183)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Covariate": "Female proportion",
                        "Method": "Meta-regression"
                    },
                    "measures": "[Estimate, S.E, 95% CI]",
                    "outcomes": "[-0.5305, 1.4575, (-3.6792\u20132.6183)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 5,
        "number_of_matches": 5
    },
    "PMC4794224_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DL1",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[966, 97%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "966"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DL3",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[719, 72%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "72%",
                        "719"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DL4",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[993, 100%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DL5",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[547, 55%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "547"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DL2*004",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[31, 3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*004"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "3%",
                        "31"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DL2*001/2/3/5",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[544, 55%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DL2*001/2/3/5"
                    },
                    "measures": [
                        "Positive Frequency, N"
                    ],
                    "outcomes": [
                        "55%",
                        "544"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DP1",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[964, 97%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DP1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "97%",
                        "964"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DS1",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[548, 55%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "55%",
                        "548"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DS2",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[581, 59%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "59%",
                        "581"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DS3",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[401, 40%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "40%",
                        "401"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DS4",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[993, 100%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS4"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR2DS5",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[281, 28%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR2DS5"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "28%",
                        "281"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR3DL1",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[929, 94%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "94%",
                        "929"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR3DL2",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[993, 100%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL2"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR3DL3",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[993, 100%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DL3"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "100%",
                        "993"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Frequency of KIR alleles",
                        "KIR genotype": "KIR3DS1",
                        "technique": "frequency analysis",
                        "statistical representation": "N (% Positive)"
                    },
                    "measures": "[frequency, percentage]",
                    "outcomes": "[354, 36%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "allele": "KIR3DS1"
                    },
                    "measures": [
                        "Positive Frequency",
                        "N"
                    ],
                    "outcomes": [
                        "36%",
                        "354"
                    ]
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 16,
        "total_ground_truth_claims": 16,
        "number_of_matches": 16
    },
    "PMC9077443_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "cabotegravir",
                        "comparison to": "TDF-FTC",
                        "events": "4",
                        "total person-years": "1956",
                        "HIV incidence": "0.20 per 100 person-years",
                        "95% CI": "0.06-0.52"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "cabotegravir",
                        "comparison to": "TDF-FTC",
                        "events": "4",
                        "total person-years": "1956",
                        "HIV incidence": "0.20 per 100 person-years",
                        "95% CI": "0.06-0.52"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "cabotegravir",
                        "comparison to": "TDF-FTC",
                        "events": "4",
                        "total person-years": "1956",
                        "HIV incidence": "0.20 per 100 person-years",
                        "95% CI": "0.06-0.52"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "cabotegravir",
                        "comparison to": "TDF-FTC",
                        "events": "4",
                        "total person-years": "1956",
                        "HIV incidence": "0.20 per 100 person-years",
                        "95% CI": "0.06-0.52"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "cabotegravir",
                        "comparison to": "TDF-FTC",
                        "events": "4",
                        "total person-years": "1956",
                        "HIV incidence": "0.20 per 100 person-years",
                        "95% CI": "0.06-0.52"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "cabotegravir",
                        "comparison to": "TDF-FTC",
                        "events": "4",
                        "total person-years": "1956",
                        "HIV incidence": "0.20 per 100 person-years",
                        "95% CI": "0.06-0.52"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "cabotegravir",
                        "comparison to": "TDF-FTC",
                        "events": "4",
                        "total person-years": "1956",
                        "HIV incidence": "0.20 per 100 person-years",
                        "95% CI": "0.06-0.52"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "cabotegravir",
                        "comparison to": "TDF-FTC",
                        "events": "4",
                        "total person-years": "1956",
                        "HIV incidence": "0.20 per 100 person-years",
                        "95% CI": "0.06-0.52"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "cabotegravir",
                        "comparison to": "TDF-FTC",
                        "events": "4",
                        "total person-years": "1956",
                        "HIV incidence": "0.20 per 100 person-years",
                        "95% CI": "0.06-0.52"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "TDF-FTC",
                        "comparison to": "cabotegravir",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85 per 100 person-years",
                        "95% CI": "1.3-2.57"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[1.85, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "TDF-FTC",
                        "comparison to": "cabotegravir",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85 per 100 person-years",
                        "95% CI": "1.3-2.57"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[1.85, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "TDF-FTC",
                        "comparison to": "cabotegravir",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85 per 100 person-years",
                        "95% CI": "1.3-2.57"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[1.85, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "TDF-FTC",
                        "comparison to": "cabotegravir",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85 per 100 person-years",
                        "95% CI": "1.3-2.57"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[1.85, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "TDF-FTC",
                        "comparison to": "cabotegravir",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85 per 100 person-years",
                        "95% CI": "1.3-2.57"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[1.85, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "TDF-FTC",
                        "comparison to": "cabotegravir",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85 per 100 person-years",
                        "95% CI": "1.3-2.57"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[1.85, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "TDF-FTC",
                        "comparison to": "cabotegravir",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85 per 100 person-years",
                        "95% CI": "1.3-2.57"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[1.85, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "TDF-FTC",
                        "comparison to": "cabotegravir",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85 per 100 person-years",
                        "95% CI": "1.3-2.57"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[1.85, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "group": "TDF-FTC",
                        "comparison to": "cabotegravir",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85 per 100 person-years",
                        "95% CI": "1.3-2.57"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[1.85, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "overall",
                        "group": "TDF-FTC",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "overall",
                        "group": "TDF-FTC",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "overall",
                        "group": "TDF-FTC",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "overall",
                        "group": "TDF-FTC",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "overall",
                        "group": "TDF-FTC",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "overall",
                        "group": "TDF-FTC",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "overall",
                        "group": "TDF-FTC",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "overall",
                        "group": "TDF-FTC",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "overall",
                        "group": "TDF-FTC",
                        "events": "36",
                        "total person-years": "1942",
                        "HIV incidence": "1.85%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.20, 0.12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "<25 years",
                        "group": "TDF-FTC",
                        "events": "20",
                        "total person-years": "851",
                        "HIV incidence": "2.34%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.35, 0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "<25 years",
                        "group": "TDF-FTC",
                        "events": "20",
                        "total person-years": "851",
                        "HIV incidence": "2.34%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.35, 0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "<25 years",
                        "group": "TDF-FTC",
                        "events": "20",
                        "total person-years": "851",
                        "HIV incidence": "2.34%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.35, 0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "<25 years",
                        "group": "TDF-FTC",
                        "events": "20",
                        "total person-years": "851",
                        "HIV incidence": "2.34%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.35, 0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "<25 years",
                        "group": "TDF-FTC",
                        "events": "20",
                        "total person-years": "851",
                        "HIV incidence": "2.34%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.35, 0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "<25 years",
                        "group": "TDF-FTC",
                        "events": "20",
                        "total person-years": "851",
                        "HIV incidence": "2.34%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.35, 0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "<25 years",
                        "group": "TDF-FTC",
                        "events": "20",
                        "total person-years": "851",
                        "HIV incidence": "2.34%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.35, 0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "<25 years",
                        "group": "TDF-FTC",
                        "events": "20",
                        "total person-years": "851",
                        "HIV incidence": "2.34%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.35, 0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "<25 years",
                        "group": "TDF-FTC",
                        "events": "20",
                        "total person-years": "851",
                        "HIV incidence": "2.34%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.35, 0.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "\u226525 years",
                        "group": "TDF-FTC",
                        "events": "16",
                        "total person-years": "1091",
                        "HIV incidence": "1.47%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.09, 0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "\u226525 years",
                        "group": "TDF-FTC",
                        "events": "16",
                        "total person-years": "1091",
                        "HIV incidence": "1.47%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.09, 0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "\u226525 years",
                        "group": "TDF-FTC",
                        "events": "16",
                        "total person-years": "1091",
                        "HIV incidence": "1.47%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.09, 0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "\u226525 years",
                        "group": "TDF-FTC",
                        "events": "16",
                        "total person-years": "1091",
                        "HIV incidence": "1.47%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.09, 0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "\u226525 years",
                        "group": "TDF-FTC",
                        "events": "16",
                        "total person-years": "1091",
                        "HIV incidence": "1.47%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.09, 0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "\u226525 years",
                        "group": "TDF-FTC",
                        "events": "16",
                        "total person-years": "1091",
                        "HIV incidence": "1.47%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.09, 0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "\u226525 years",
                        "group": "TDF-FTC",
                        "events": "16",
                        "total person-years": "1091",
                        "HIV incidence": "1.47%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.09, 0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "\u226525 years",
                        "group": "TDF-FTC",
                        "events": "16",
                        "total person-years": "1091",
                        "HIV incidence": "1.47%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.09, 0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "age",
                        "sub-subgroup": "\u226525 years",
                        "group": "TDF-FTC",
                        "events": "16",
                        "total person-years": "1091",
                        "HIV incidence": "1.47%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.09, 0.09]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "DMPA",
                        "group": "TDF-FTC",
                        "events": "21",
                        "total person-years": "1000",
                        "HIV incidence": "2.10%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.30, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "DMPA",
                        "group": "TDF-FTC",
                        "events": "21",
                        "total person-years": "1000",
                        "HIV incidence": "2.10%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.30, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "DMPA",
                        "group": "TDF-FTC",
                        "events": "21",
                        "total person-years": "1000",
                        "HIV incidence": "2.10%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.30, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "DMPA",
                        "group": "TDF-FTC",
                        "events": "21",
                        "total person-years": "1000",
                        "HIV incidence": "2.10%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.30, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "DMPA",
                        "group": "TDF-FTC",
                        "events": "21",
                        "total person-years": "1000",
                        "HIV incidence": "2.10%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.30, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "DMPA",
                        "group": "TDF-FTC",
                        "events": "21",
                        "total person-years": "1000",
                        "HIV incidence": "2.10%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.30, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "DMPA",
                        "group": "TDF-FTC",
                        "events": "21",
                        "total person-years": "1000",
                        "HIV incidence": "2.10%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.30, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "DMPA",
                        "group": "TDF-FTC",
                        "events": "21",
                        "total person-years": "1000",
                        "HIV incidence": "2.10%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.30, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "DMPA",
                        "group": "TDF-FTC",
                        "events": "21",
                        "total person-years": "1000",
                        "HIV incidence": "2.10%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.30, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "NET-EN",
                        "group": "TDF-FTC",
                        "events": "6",
                        "total person-years": "182",
                        "HIV incidence": "3.30%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.57, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "NET-EN",
                        "group": "TDF-FTC",
                        "events": "6",
                        "total person-years": "182",
                        "HIV incidence": "3.30%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.57, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "NET-EN",
                        "group": "TDF-FTC",
                        "events": "6",
                        "total person-years": "182",
                        "HIV incidence": "3.30%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.57, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "NET-EN",
                        "group": "TDF-FTC",
                        "events": "6",
                        "total person-years": "182",
                        "HIV incidence": "3.30%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.57, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "NET-EN",
                        "group": "TDF-FTC",
                        "events": "6",
                        "total person-years": "182",
                        "HIV incidence": "3.30%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.57, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "NET-EN",
                        "group": "TDF-FTC",
                        "events": "6",
                        "total person-years": "182",
                        "HIV incidence": "3.30%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.57, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "NET-EN",
                        "group": "TDF-FTC",
                        "events": "6",
                        "total person-years": "182",
                        "HIV incidence": "3.30%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.57, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "NET-EN",
                        "group": "TDF-FTC",
                        "events": "6",
                        "total person-years": "182",
                        "HIV incidence": "3.30%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.57, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "NET-EN",
                        "group": "TDF-FTC",
                        "events": "6",
                        "total person-years": "182",
                        "HIV incidence": "3.30%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.57, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Implant",
                        "group": "TDF-FTC",
                        "events": "8",
                        "total person-years": "607",
                        "HIV incidence": "1.32%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Implant",
                        "group": "TDF-FTC",
                        "events": "8",
                        "total person-years": "607",
                        "HIV incidence": "1.32%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Implant",
                        "group": "TDF-FTC",
                        "events": "8",
                        "total person-years": "607",
                        "HIV incidence": "1.32%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Implant",
                        "group": "TDF-FTC",
                        "events": "8",
                        "total person-years": "607",
                        "HIV incidence": "1.32%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Implant",
                        "group": "TDF-FTC",
                        "events": "8",
                        "total person-years": "607",
                        "HIV incidence": "1.32%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Implant",
                        "group": "TDF-FTC",
                        "events": "8",
                        "total person-years": "607",
                        "HIV incidence": "1.32%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.06]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Implant contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "8/607 (1.32%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.06, 0.00-1.16]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Other",
                        "group": "TDF-FTC",
                        "events": "1",
                        "total person-years": "152",
                        "HIV incidence": "0.66%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Other",
                        "group": "TDF-FTC",
                        "events": "1",
                        "total person-years": "152",
                        "HIV incidence": "0.66%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Other",
                        "group": "TDF-FTC",
                        "events": "1",
                        "total person-years": "152",
                        "HIV incidence": "0.66%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Other",
                        "group": "TDF-FTC",
                        "events": "1",
                        "total person-years": "152",
                        "HIV incidence": "0.66%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Other",
                        "group": "TDF-FTC",
                        "events": "1",
                        "total person-years": "152",
                        "HIV incidence": "0.66%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "contraceptive method",
                        "sub-subgroup": "Other",
                        "group": "TDF-FTC",
                        "events": "1",
                        "total person-years": "152",
                        "HIV incidence": "0.66%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.32]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Other contraceptive method",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "1/152 (0.66%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.32, 0.01-9.89]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": "\u226430 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "27",
                        "total person-years": "1447",
                        "HIV incidence": "1.87%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.29, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": "\u226430 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "27",
                        "total person-years": "1447",
                        "HIV incidence": "1.87%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.29, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": "\u226430 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "27",
                        "total person-years": "1447",
                        "HIV incidence": "1.87%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.29, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": "\u226430 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "27",
                        "total person-years": "1447",
                        "HIV incidence": "1.87%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.29, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": "\u226430 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "27",
                        "total person-years": "1447",
                        "HIV incidence": "1.87%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.29, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": "\u226430 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "27",
                        "total person-years": "1447",
                        "HIV incidence": "1.87%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.29, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": "\u226430 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "27",
                        "total person-years": "1447",
                        "HIV incidence": "1.87%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[0.29, 0.16]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": ">30 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "9",
                        "total person-years": "495",
                        "HIV incidence": "1.82%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Overall",
                        "Events per total PY in cabotegravir group": "4/1956 (0.20%)",
                        "Events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                        "Method": "Median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.12, 0.05-0.31, <0.0001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": ">30 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "9",
                        "total person-years": "495",
                        "HIV incidence": "1.82%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age <25 years",
                        "Events per total PY in cabotegravir group": "3/866 (0.35%)",
                        "Events per total PY in TDF-FTC group": "20/851 (2.34%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.17, 0.05-0.54, 0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": ">30 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "9",
                        "total person-years": "495",
                        "HIV incidence": "1.82%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Age \u226525 years",
                        "Events per total PY in cabotegravir group": "1/1090 (0.09%)",
                        "Events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.09, 0.02-0.49]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": ">30 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "9",
                        "total person-years": "495",
                        "HIV incidence": "1.82%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "DMPA contraceptive method",
                        "Events per total PY in cabotegravir group": "3/1009 (0.30%)",
                        "Events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.05-0.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": ">30 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "9",
                        "total person-years": "495",
                        "HIV incidence": "1.82%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "NET-EN contraceptive method",
                        "Events per total PY in cabotegravir group": "1/175 (0.57%)",
                        "Events per total PY in TDF-FTC group": "6/182 (3.30%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.22, 0.03-1.48]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": ">30 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "9",
                        "total person-years": "495",
                        "HIV incidence": "1.82%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI \u226430 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "4/1389 (0.29%)",
                        "Events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                        "Method": "Standard estimation method (no indication of zero infections)"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.16, 0.06-0.45]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "ITT analysis",
                        "analysis type": "cabotegravir effectiveness",
                        "subgroup": "body-mass index",
                        "sub-subgroup": ">30 kg/m\u00b2",
                        "group": "TDF-FTC",
                        "events": "9",
                        "total person-years": "495",
                        "HIV incidence": "1.82%"
                    },
                    "measures": "[HIV incidence, HR]",
                    "outcomes": "[., 0.05]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "BMI >30 kg/m\u00b2",
                        "Events per total PY in cabotegravir group": "0",
                        "Events per total PY in TDF-FTC group": "9/495 (1.82%)",
                        "Method": "Firth's method used due to zero infections in cabotegravir group"
                    },
                    "measures": "[HR, 95% CI]",
                    "outcomes": "[0.05, 0.00-0.96]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 11,
        "total_ground_truth_claims": 9,
        "number_of_matches": 3
    },
    "PMC10294491_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "trial": "DISCOVER",
                        "analysis": "primary outcome analysis",
                        "group": "TDF/FTC",
                        "no. subjects": "2693",
                        "PYFU": "4386",
                        "incident HIV infections": "11",
                        "incidence rate": "0.251 per 100 PYFU",
                        "rate ratio": "REF"
                    },
                    "measures": "[incidence rate, rate ratio]",
                    "outcomes": "[0.251 per 100 PYFU, REF]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TDF/FTC",
                        "No. subjects": "2693",
                        "PYFU": "4386",
                        "Incident HIV infections": "11",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.251, REF]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "trial": "DISCOVER",
                        "analysis": "primary outcome analysis",
                        "group": "TAF/FTC",
                        "no. subjects": "2694",
                        "PYFU": "4370",
                        "incident HIV infections": "6",
                        "incidence rate": "0.137 per 100 PYFU",
                        "rate ratio": "0.55 (0.20, 1.48)"
                    },
                    "measures": "[incidence rate, rate ratio]",
                    "outcomes": "[0.137 per 100 PYFU, 0.55 (0.20, 1.48)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Original analysis on rate ratio scale",
                        "Group": "TAF/FTC",
                        "No. subjects": "2694",
                        "PYFU": "4370",
                        "Incident HIV infections": "6",
                        "Method": "Rate ratio analysis"
                    },
                    "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                    "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "trial": "DISCOVER",
                        "analysis": "re-analysis using an averted infections framework",
                        "group": "TDF/FTC",
                        "PYFU": "4386",
                        "observed infections": "11",
                        "predicted infections": "90.4",
                        "averted infections": "79.4",
                        "averted infections ratio": "REF"
                    },
                    "measures": "[averted infections, averted infections ratio]",
                    "outcomes": "[79.4, REF]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TDF/FTC",
                        "PYFU": "4386",
                        "Observed infections": "11",
                        "Predicted infections": "90.4",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[79.4, REF]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "trial": "DISCOVER",
                        "analysis": "re-analysis using an averted infections framework",
                        "group": "TAF/FTC",
                        "PYFU": "4370",
                        "observed infections": "6",
                        "predicted infections": "90.0",
                        "averted infections": "84.0",
                        "averted infections ratio": "1.06 (0.96\u20131.17)"
                    },
                    "measures": "[averted infections, averted infections ratio]",
                    "outcomes": "[84.0, 1.06 (0.96\u20131.17)]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Analysis": "Re-analysis using an averted infections framework",
                        "Group": "TAF/FTC",
                        "PYFU": "4370",
                        "Observed infections": "6",
                        "Predicted infections": "90.0",
                        "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                    },
                    "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                    "outcomes": "[84.0, 1.06 (0.96-1.17)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 4,
        "number_of_matches": 4
    },
    "PMC6158807_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "incidence rates of non-AIDS composite events",
                        "endpoint": "composite endpoint",
                        "number of patients": "692",
                        "statistical test": "long rank test",
                        "p value": "< 0.001"
                    },
                    "measures": "[number of events, person-year of follow-up, rate per 100 person-year, 95% CI]",
                    "outcomes": "[123, 4071, 3.02, 2.53\u20133.61]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Composite endpoint (all participants)",
                        "Sample size": "692",
                        "No. of events": "123",
                        "Person-years of follow-up": "4071",
                        "Method": "Event rate across total follow-up"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[3.02 (2.53\u20133.61)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "incidence rates of non-AIDS composite events",
                        "endpoint": "composite endpoint",
                        "CD4/CD8 ratio": "< 0.3",
                        "statistical test": "long rank test",
                        "p value": "< 0.001"
                    },
                    "measures": "[number of events, person-year of follow-up, rate per 100 person-year, 95% CI]",
                    "outcomes": "[21, 184, 11.42, 7.45\u201317.52]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio < 0.3",
                        "No. of events": "21",
                        "Person-years of follow-up": "184",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[11.42 (7.45\u201317.52)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "incidence rates of non-AIDS composite events",
                        "endpoint": "composite endpoint",
                        "CD4/CD8 ratio": "0.30\u20130.45",
                        "statistical test": "long rank test",
                        "p value": "< 0.001"
                    },
                    "measures": "[number of events, person-year of follow-up, rate per 100 person-year, 95% CI]",
                    "outcomes": "[28, 496, 5.64, 3.90\u20138.17]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio 0.30\u20130.45",
                        "No. of events": "28",
                        "Person-years of follow-up": "496",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[5.64 (3.90\u20138.17)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "incidence rates of non-AIDS composite events",
                        "endpoint": "composite endpoint",
                        "CD4/CD8 ratio": "> 0.45",
                        "statistical test": "long rank test",
                        "p value": "< 0.001"
                    },
                    "measures": "[number of events, person-year of follow-up, rate per 100 person-year, 95% CI]",
                    "outcomes": "[72, 3227, 2.23, 1.77\u20132.81]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "Current CD4/CD8 ratio > 0.45",
                        "No. of events": "72",
                        "Person-years of follow-up": "3227",
                        "Method": "Rate stratified by CD4/CD8 ratio group"
                    },
                    "measures": "[Rate per 100 person-years (95% CI)]",
                    "outcomes": "[2.23 (1.77\u20132.81)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 4,
        "total_ground_truth_claims": 4,
        "number_of_matches": 4
    },
    "PMC7522205_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Total",
                        "patients": "2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Total",
                        "patients": "2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Total",
                        "patients": "2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Total",
                        "patients": "2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Total",
                        "patients": "2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Total",
                        "patients": "2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Total",
                        "patients": "2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[87, 46\u2013128, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Total",
                        "patients": "2845 (100.0)",
                        "CD4+ median (IQR)": "160 (49\u2013310)"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[72, 37\u2013107, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF01_AE",
                        "patients": "1687 (59.3)",
                        "CD4+ median (IQR)": "111 (31\u2013279)"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF07_BC",
                        "patients": "254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[139 (117\u2013161), <0.001, 113 (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF07_BC",
                        "patients": "254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[139 (117\u2013161), <0.001, 113 (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF07_BC",
                        "patients": "254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[139 (117\u2013161), <0.001, 113 (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF07_BC",
                        "patients": "254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[139 (117\u2013161), <0.001, 113 (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF07_BC",
                        "patients": "254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[139 (117\u2013161), <0.001, 113 (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF07_BC",
                        "patients": "254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[139 (117\u2013161), <0.001, 113 (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[87, 46\u2013128, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF07_BC",
                        "patients": "254 (8.9)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[139 (117\u2013161), <0.001, 113 (86\u2013140), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[72, 37\u2013107, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF08_BC",
                        "patients": "728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[94 (73\u2013115), <0.001, 80 (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF08_BC",
                        "patients": "728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[94 (73\u2013115), <0.001, 80 (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF08_BC",
                        "patients": "728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[94 (73\u2013115), <0.001, 80 (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF08_BC",
                        "patients": "728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[94 (73\u2013115), <0.001, 80 (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF08_BC",
                        "patients": "728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[94 (73\u2013115), <0.001, 80 (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF08_BC",
                        "patients": "728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[94 (73\u2013115), <0.001, 80 (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[87, 46\u2013128, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "CRF08_BC",
                        "patients": "728 (25.6)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[94 (73\u2013115), <0.001, 80 (65\u201395), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[72, 37\u2013107, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Others",
                        "patients": "176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[87 (46\u2013128), <0.001, 72 (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF01_AE",
                        "Patients": "1687 (59.3%)",
                        "CD4+ median (IQR)": "111 (31\u2013279)",
                        "Reference group": "Yes"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[0, \u2013, \u2013]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Others",
                        "patients": "176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[87 (46\u2013128), <0.001, 72 (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[139, 117\u2013161, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Others",
                        "patients": "176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[87 (46\u2013128), <0.001, 72 (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF07_BC",
                        "Patients": "254 (8.9%)",
                        "CD4+ median (IQR)": "250 (156\u2013377)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[113, 86\u2013140, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Others",
                        "patients": "176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[87 (46\u2013128), <0.001, 72 (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[94, 73\u2013115, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Others",
                        "patients": "176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[87 (46\u2013128), <0.001, 72 (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "CRF08_BC",
                        "Patients": "728 (25.6%)",
                        "CD4+ median (IQR)": "205 (108\u2013327)",
                        "Vairables adjusted for": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, and year of HIV infection diagnosis"
                    },
                    "measures": "[Adjusted Coefficient, 95% CI, P]",
                    "outcomes": "[80, 65\u201395, <0.001]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "observational",
                        "patient population": "newly diagnosed HIV patients",
                        "analysis": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                        "HIV-1 genotype": "Others",
                        "patients": "176 (6.2)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[unadjusted coefficient, adjusted coefficient]",
                    "outcomes": "[87 (46\u2013128), <0.001, 72 (37\u2013107), <0.001]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV-1 Genotype": "Others",
                        "Patients": "176 (6.2%)",
                        "CD4+ median (IQR)": "198 (89\u2013355)"
                    },
                    "measures": "[Unadjusted Coefficient, 95% CI, P]",
                    "outcomes": "[87, 46\u2013128, <0.001]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 8,
        "number_of_matches": 2
    },
    "PMC7414801_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[381 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[114 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[43 (11), 11]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[382 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[115 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[73 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[44 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[26 (7), 7]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "As-randomized",
                        "n": "382"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[17 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, HIV VL]",
                    "outcomes": "[330 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, HIV VL]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, HIV VL]",
                    "outcomes": "[65 (20), 20]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, HIV VL]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, HIV VL]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, HIV VL]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[HIV detection visit, CD4]",
                    "outcomes": "[331 (100), 100]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M3, CD4]",
                    "outcomes": "[99 (30), 30]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M6, CD4]",
                    "outcomes": "[64 (19), 19]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M9, CD4]",
                    "outcomes": "[40 (12), 12]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M12, CD4]",
                    "outcomes": "[25 (8), 8]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "133",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "135",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[36.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "HIV detection visit": "114",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[39.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[19.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[17.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.2]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "As-randomized",
                        "sample size": 382,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[13.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "106",
                        "method": "DMPA-IM",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[23.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "118",
                        "method": "Copper IUD",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[34.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "HIV detection visit": "107",
                        "method": "LNG implant",
                        "month": "M3"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[41.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[9.3]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M6"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[18.1]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[11.8]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M9"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[2.4]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[6.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M12"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[15.6]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "DMPA-IM",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[7.7]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "Copper IUD",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[10.0]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV Seroconverter",
                        "analysis": "Summary of HIV Seroconverter Data",
                        "data type": "Available by Months Since HIV Detection Visit",
                        "exclusion criteria": "women infected at baseline and visits following ART initiation",
                        "group": "Continuous use",
                        "n": "331"
                    },
                    "measures": "[M15, CD4]",
                    "outcomes": "[14 (4), 4]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "summary": "HIV Seroconverter Data",
                        "timepoint": "HIV detection visit",
                        "group": "Consistent-use",
                        "sample size": 331,
                        "method": "LNG implant",
                        "month": "M15"
                    },
                    "measures": "[Attended visit %]",
                    "outcomes": "[14.3]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 24,
        "total_ground_truth_claims": 30,
        "number_of_matches": 0
    },
    "PMC9624454_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "total number": "1024"
                    },
                    "measures": "[CMV viremia, P Value]",
                    "outcomes": "[314 (30.7), -]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[30.7%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "all children"
                    },
                    "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
                    "outcomes": "[59 (5.8), -]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.8%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "all children"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics, P Value]",
                    "outcomes": "[2.3 (1.9\u20132.7), -]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "All children",
                        "Total No.": "1024",
                        "Method": "Overall CMV viremia analysis across all groups"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV unexposed"
                    },
                    "measures": "[CMV viremia, P Value]",
                    "outcomes": "[253 (29.0), -]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia (%)]",
                    "outcomes": "[29.0%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV unexposed"
                    },
                    "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
                    "outcomes": "[45 (5.2), -]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%)]",
                    "outcomes": "[5.2%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV unexposed"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics, P Value]",
                    "outcomes": "[2.3 (1.9\u20132.7), -]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV unexposed",
                        "Total No.": "872",
                        "Method": "Reference group for all comparisons"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics (Median, IQR)]",
                    "outcomes": "[2.3 (1.9\u20132.7)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV exposed"
                    },
                    "measures": "[CMV viremia, P Value]",
                    "outcomes": "[45 (38.1), 0.061]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[38.1%, 0.061]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV exposed"
                    },
                    "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
                    "outcomes": "[10 (8.5), 0.18]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[8.5%, 0.18]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV exposed"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics, P Value]",
                    "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed",
                        "Total No.": "118",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (2.0\u20132.9), 0.24]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV exposed uninfected"
                    },
                    "measures": "[CMV viremia, P Value]",
                    "outcomes": "[36 (37.1), 0.088]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[37.1%, 0.088]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV exposed uninfected"
                    },
                    "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
                    "outcomes": "[6 (6.2), 0.56]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[6.2%, 0.56]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV exposed uninfected"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics, P Value]",
                    "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV exposed uninfected",
                        "Total No.": "97",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[2.4 (1.9\u20132.7), 0.74]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV infected"
                    },
                    "measures": "[CMV viremia, P Value]",
                    "outcomes": "[6 (40.0), 0.39]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia (%), P Value]",
                    "outcomes": "[40.0%, 0.39]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV infected"
                    },
                    "measures": "[CMV viremia \u2264 1000 IU/mL, P Value]",
                    "outcomes": "[3 (20.0), 0.015]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[CMV Viremia \u2265 1000 IU/mL (%), P Value]",
                    "outcomes": "[20.0%, 0.015]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study population": "hospitalized children",
                        "analysis": "CMV detection, high-level viremia, and median viral loads",
                        "stratification": "HIV exposure or infection",
                        "HIV exposure": "HIV infected"
                    },
                    "measures": "[log10 CMV IU/mL in Viremics, P Value]",
                    "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "HIV Status": "HIV infected",
                        "Total No.": "15",
                        "Method": "Comparison to HIV unexposed group"
                    },
                    "measures": "[log10 CMV IU/mL (Median, IQR), P Value]",
                    "outcomes": "[3.2 (2.6\u20135.3), 0.012]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 15,
        "total_ground_truth_claims": 15,
        "number_of_matches": 15
    },
    "PMC4549947_4": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Females",
                        "statistical representation": "OR (95% CI)"
                    },
                    "measures": "[effect size, P]",
                    "outcomes": "[1.3, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "gender": "females",
                        "p-interaction": "0.35"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.3]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Males",
                        "statistical representation": "OR (95% CI)"
                    },
                    "measures": "[effect size, P]",
                    "outcomes": "[3.5, 0.008]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "gender": "males",
                        "p-interaction": "0.35"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.5, 1.5\u20135.5, 0.008]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Hispanics",
                        "statistical representation": "OR"
                    },
                    "measures": "[effect size, NA]",
                    "outcomes": "[2.6, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "African American",
                        "statistical representation": "OR (95% CI)"
                    },
                    "measures": "[effect size, P]",
                    "outcomes": "[3.1, 0.01]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.05"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[3.1, 2.3\u20133.5, 0.01]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Alcohol use",
                        "statistical representation": "OR"
                    },
                    "measures": "[effect size, NA]",
                    "outcomes": "[2.6, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "executive function",
                        "context": "alcohol use"
                    },
                    "measures": "[OR]",
                    "outcomes": "[2.6]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Females and Males",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.35, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "p-intraction": "0.013"
                    },
                    "measures": "[OR]",
                    "outcomes": "[0.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Females and Males",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.35, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "p-interaction": "0.013"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.8, 1.2\u20132.9, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Females and Males",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.35, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Females and Males",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.35, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Females and Males",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.35, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Hispanics and African American",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.05, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "p-intraction": "0.013"
                    },
                    "measures": "[OR]",
                    "outcomes": "[0.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Hispanics and African American",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.05, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "p-interaction": "0.013"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.8, 1.2\u20132.9, 0.01]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Hispanics and African American",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.05, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Hispanics and African American",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.05, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "executive function",
                        "group": "Hispanics and African American",
                        "statistical representation": "p interaction"
                    },
                    "measures": "[interaction P, NA]",
                    "outcomes": "[0.05, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "cognitive flexibility",
                        "group": "Females",
                        "statistical representation": "OR"
                    },
                    "measures": "[effect size, NA]",
                    "outcomes": "[0.9, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "females",
                        "p-intraction": "0.013"
                    },
                    "measures": "[OR]",
                    "outcomes": "[0.9]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "cognitive flexibility",
                        "group": "Males",
                        "statistical representation": "OR (95% CI)"
                    },
                    "measures": "[effect size, P]",
                    "outcomes": "[1.8, 0.01]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "gender": "males",
                        "p-interaction": "0.013"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.8, 1.2\u20132.9, 0.01]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "cognitive flexibility",
                        "group": "Hispanics",
                        "statistical representation": "OR"
                    },
                    "measures": "[effect size, NA]",
                    "outcomes": "[1.9, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "Hispanics",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.9]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "cognitive flexibility",
                        "group": "African American",
                        "statistical representation": "OR"
                    },
                    "measures": "[effect size, NA]",
                    "outcomes": "[1.5, NA]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "race/ethnicity": "African American",
                        "p-interaction": "0.72"
                    },
                    "measures": "[OR]",
                    "outcomes": "[1.5]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "gene": "DRD2",
                        "variant": "rs6277",
                        "trait": "cognitive flexibility",
                        "group": "Alcohol use",
                        "statistical representation": "OR (95% CI)"
                    },
                    "measures": "[effect size, P]",
                    "outcomes": "[1.6, 0.03]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "DRD2 associations with cognitive flexibility and executive function",
                        "variant": "DRD2 rs6277",
                        "trait": "cognitive flexibility",
                        "context": "alcohol use",
                        "p-interaction": "0.32"
                    },
                    "measures": "[OR, 95% CI, p-value]",
                    "outcomes": "[1.6, 1.4\u20132.4, 0.03]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 15,
        "total_ground_truth_claims": 10,
        "number_of_matches": 10
    },
    "PMC6694514_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "12",
                        "percentage of total G3+ events": "30.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[12, 30.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Hepatobiliary disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "12",
                        "30.0%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "15",
                        "percentage of total G3+ events": "25.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[15, 25.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Hepatobiliary disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "15",
                        "25.0%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "7",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[7, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "7",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[7, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "7",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[7, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "7",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[7, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "7",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[7, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "7",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[7, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "7",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[7, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "7",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[7, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "21.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 21.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "21.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 21.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "21.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 21.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "21.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 21.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "21.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 21.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "21.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 21.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "21.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 21.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Respiratory and thoracic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "21.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 21.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "6",
                        "percentage of total G3+ events": "15.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[6, 15.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "6",
                        "percentage of total G3+ events": "15.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[6, 15.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "6",
                        "percentage of total G3+ events": "15.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[6, 15.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "6",
                        "percentage of total G3+ events": "15.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[6, 15.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "6",
                        "percentage of total G3+ events": "15.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[6, 15.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "6",
                        "percentage of total G3+ events": "15.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[6, 15.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "6",
                        "percentage of total G3+ events": "15.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[6, 15.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "6",
                        "percentage of total G3+ events": "15.0%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[6, 15.0%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "10",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[10, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "10",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[10, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "10",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[10, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "10",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[10, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "10",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[10, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "10",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[10, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "10",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[10, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Blood and lymphatic disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "10",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[10, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "5",
                        "percentage of total G3+ events": "8.3%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[5, 8.3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "5",
                        "percentage of total G3+ events": "8.3%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[5, 8.3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "5",
                        "percentage of total G3+ events": "8.3%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[5, 8.3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "5",
                        "percentage of total G3+ events": "8.3%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[5, 8.3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "5",
                        "percentage of total G3+ events": "8.3%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[5, 8.3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "5",
                        "percentage of total G3+ events": "8.3%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[5, 8.3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "5",
                        "percentage of total G3+ events": "8.3%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[5, 8.3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Infections and infestations",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "5",
                        "percentage of total G3+ events": "8.3%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[5, 8.3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "3",
                        "percentage of total G3+ events": "7.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[3, 7.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "4",
                        "percentage of total G3+ events": "6.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[4, 6.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "4",
                        "percentage of total G3+ events": "6.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[4, 6.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "4",
                        "percentage of total G3+ events": "6.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[4, 6.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "4",
                        "percentage of total G3+ events": "6.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[4, 6.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "4",
                        "percentage of total G3+ events": "6.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[4, 6.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "4",
                        "percentage of total G3+ events": "6.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[4, 6.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "4",
                        "percentage of total G3+ events": "6.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[4, 6.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Metabolism and nutrition disorders",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "4",
                        "percentage of total G3+ events": "6.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[4, 6.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "9",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[9, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "9",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[9, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "9",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[9, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "9",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[9, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "9",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[9, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "9",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[9, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "9",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[9, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-positive",
                        "grade": "3 or 4",
                        "event frequency": "9",
                        "percentage of total G3+ events": "17.5%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[9, 17.5%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "17.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Infections and infestations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "9",
                        "15.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Gastrointestinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "8",
                        "13.3%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "5",
                        "12.5%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Investigations",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "7",
                        "11.7%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-positive"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "4",
                        "10.0%"
                    ]
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "REMoxTB trial",
                        "adverse event type": "Other",
                        "HIV status": "HIV-negative",
                        "grade": "3 or 4",
                        "event frequency": "13",
                        "percentage of total G3+ events": "16.7%"
                    },
                    "measures": "[adverse event frequency, percentage of total G3+ events]",
                    "outcomes": "[13, 16.7%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "trial": "REMoxTB",
                        "population": "matched population",
                        "phase": "enrolment",
                        "comparison": "HIV-positive vs HIV-negative patients",
                        "event severity": "Grade 3 or 4",
                        "event type": "Adverse Events (AEs)",
                        "filter": "five most frequently reported SOCs",
                        "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                        "HIV status": "HIV-negative"
                    },
                    "measures": [
                        "Count",
                        "Percentage of G3+ Events"
                    ],
                    "outcomes": [
                        "6",
                        "10.0%"
                    ]
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 12,
        "total_ground_truth_claims": 10,
        "number_of_matches": 2
    },
    "PMC6937831_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "category": "Death category of individuals living with HIV",
                        "death type": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "number of deaths": "6",
                        "percentage": "4%"
                    },
                    "measures": "[number of deaths, percentage]",
                    "outcomes": "[6, 4%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "6",
                        "4%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "category": "Death category of individuals living with HIV",
                        "death type": "Non-AIDS-Related Death (NARD)",
                        "cause": "Other diseases",
                        "number of deaths": "10",
                        "percentage": "8%"
                    },
                    "measures": "[number of deaths, percentage]",
                    "outcomes": "[10, 8%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "10",
                        "8%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "category": "Death category of individuals living with HIV",
                        "death type": "Non-AIDS-Related Death (NARD)",
                        "cause": "CVD",
                        "number of deaths": "12",
                        "percentage": "9%"
                    },
                    "measures": "[number of deaths, percentage]",
                    "outcomes": "[12, 9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "CVD"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "12",
                        "9%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "category": "Death category of individuals living with HIV",
                        "death type": "Non-AIDS-Related Death (NARD)",
                        "cause": "Hepatic/liver-related",
                        "number of deaths": "34",
                        "percentage": "24%"
                    },
                    "measures": "[number of deaths, percentage]",
                    "outcomes": "[34, 24%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "Hepatic/liver-related"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "34",
                        "24%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "category": "Death category of individuals living with HIV",
                        "death type": "Non-AIDS-Related Death (NARD)",
                        "cause": "External death",
                        "number of deaths": "78",
                        "percentage": "55%"
                    },
                    "measures": "[number of deaths, percentage]",
                    "outcomes": "[78, 55%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "Non-AIDS-Related Death (NARD)",
                        "cause": "External death",
                        "Cause of death": "sudden death, including accident, overdose and suicide"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "78",
                        "55%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "category": "Death category of individuals living with HIV",
                        "death type": "AIDS-Related Death (ARD)",
                        "cause": "Other diseases",
                        "number of deaths": "2",
                        "percentage": "1%"
                    },
                    "measures": "[number of deaths, percentage]",
                    "outcomes": "[2, 1%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Other diseases",
                        "ARM classification": "CD4 ceel count lowen than 200 cells/mm2",
                        "NARD classification": "CD4 ceel count higher than 200 cells/mm2"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "2",
                        "1%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "category": "Death category of individuals living with HIV",
                        "death type": "AIDS-Related Death (ARD)",
                        "cause": "Cancer",
                        "number of deaths": "8",
                        "percentage": "3%"
                    },
                    "measures": "[number of deaths, percentage]",
                    "outcomes": "[8, 3%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Cancer",
                        "Protocol": "CoDe",
                        "ARM classification": "AIDS-related cancers",
                        "NARD classification": "Non-AIDS-related cancers"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "8",
                        "3%"
                    ]
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "category": "Death category of individuals living with HIV",
                        "death type": "AIDS-Related Death (ARD)",
                        "cause": "Opportunistic",
                        "number of deaths": "241",
                        "percentage": "96%"
                    },
                    "measures": "[number of deaths, percentage]",
                    "outcomes": "[241, 96%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "population": "Individuals living with HIV",
                        "category": "AIDS-Related Death (ARD)",
                        "cause": "Opportunistic"
                    },
                    "measures": [
                        "Number of deaths",
                        "Percentage"
                    ],
                    "outcomes": [
                        "241",
                        "96%"
                    ]
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 11,
        "total_ground_truth_claims": 8,
        "number_of_matches": 8
    },
    "PMC8340029_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "observational",
                        "PrEP access": "on-site",
                        "time period": "before access",
                        "analysis": "incidence",
                        "statistical representation": "rate",
                        "unit": "person-years",
                        "number of infections": "133",
                        "person-years": "2860",
                        "incidence": "4.65%"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[4.65%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "Before access",
                        "data representation": "incidence",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "133",
                        "person-years": "2860",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[4.65%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "observational",
                        "PrEP access": "on-site",
                        "time period": "after access",
                        "analysis": "incidence",
                        "statistical representation": "rate",
                        "unit": "person-years",
                        "number of infections": "12",
                        "person-years": "556",
                        "incidence": "2.16%"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[2.16%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "Number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.16%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "observational",
                        "PrEP access": "on-site",
                        "time period": "after access",
                        "analysis": "incidence rate ratio",
                        "statistical representation": "rate ratio (95% CI)",
                        "adjusted for": "study site and randomisation group",
                        "incidence rate ratio": "0.45 (0.25-0.81)",
                        "p value": "0.0076"
                    },
                    "measures": "[incidence rate ratio, p value]",
                    "outcomes": "[0.45 (0.25-0.81), 0.0076]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, 95% CI, p value]",
                    "outcomes": "[0.45, 0.25-0.81, 0.0076]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "observational",
                        "PrEP access": "on-site",
                        "time period": "after access",
                        "analysis": "incidence rate ratio",
                        "statistical representation": "rate ratio (95% CI)",
                        "adjusted for": "study site and randomisation group",
                        "incidence rate ratio": "0.45 (0.25-0.82)",
                        "p value": "0.0085"
                    },
                    "measures": "[incidence rate ratio, p value]",
                    "outcomes": "[0.45 (0.25-0.82), 0.0085]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "Including study visits with on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "12",
                        "person-years": "556",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.45, (0.25-0.82), 0.0085]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "observational",
                        "PrEP access": "on-site",
                        "time period": "before access",
                        "analysis": "incidence",
                        "statistical representation": "rate",
                        "unit": "person-years",
                        "number of infections": "46",
                        "person-years": "919",
                        "incidence": "5.00%"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[5.00%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "Before access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "46",
                        "person-years": "919",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[5.00%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "observational",
                        "PrEP access": "on-site",
                        "time period": "after access",
                        "analysis": "incidence",
                        "statistical representation": "rate",
                        "unit": "person-years",
                        "number of infections": "11",
                        "person-years": "481",
                        "incidence": "2.29%"
                    },
                    "measures": "[incidence]",
                    "outcomes": "[2.29%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Incidence]",
                    "outcomes": "[2.29%]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "observational",
                        "PrEP access": "on-site",
                        "time period": "after access",
                        "analysis": "incidence rate ratio",
                        "statistical representation": "rate ratio (95% CI)",
                        "adjusted for": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)",
                        "incidence rate ratio": "0.44 (0.23-0.85)",
                        "p value": "0.015"
                    },
                    "measures": "[incidence rate ratio, p value]",
                    "outcomes": "[0.44 (0.23-0.85), 0.015]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.44, (0.23-0.85), 0.015]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study design": "observational",
                        "PrEP access": "on-site",
                        "time period": "after access",
                        "analysis": "incidence rate ratio",
                        "statistical representation": "rate ratio (95% CI)",
                        "adjusted for": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)",
                        "incidence rate ratio": "0.43 (0.22-0.83)",
                        "p value": "0.012"
                    },
                    "measures": "[incidence rate ratio, p value]",
                    "outcomes": "[0.43 (0.22-0.83), 0.012]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Effect of on-site PrEP access on HIV incidence",
                        "context": "180 days before versus 180 days after on-site PrEP access",
                        "group": "After access",
                        "PrEP": "pre-exposure prophylaxis",
                        "number of infections": "11",
                        "person-years": "481",
                        "adjustments": "study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
                    },
                    "measures": "[Adjusted incidence rate ratio, (95% CI), p value]",
                    "outcomes": "[0.43, (0.22-0.83), 0.012]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 8,
        "total_ground_truth_claims": 8,
        "number_of_matches": 8
    },
    "PMC8391097_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "HIV Incidence Rate Estimates",
                        "PrEP status": "Overall",
                        "exclusion": "individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage",
                        "HIV infections": "91",
                        "total No. of individuals": "13 861",
                        "total follow-up": "26 210 person-years"
                    },
                    "measures": "[incidence, 95% CI]",
                    "outcomes": "[0.35, 0.28-0.43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Overall",
                        "HIV infections number": "91",
                        "Number of individuals": "13 861",
                        "total follow-up (person-years)": "26 210",
                        "incidence": "per 100 person-years",
                        "exclusion criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[0.35 (0.28-0.43)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "HIV Incidence Rate Estimates",
                        "PrEP status": "Linked but not prescribed PrEP",
                        "HIV infections": "36",
                        "total No. of individuals": "3013",
                        "total follow-up": "4119 person-years"
                    },
                    "measures": "[incidence, 95% CI]",
                    "outcomes": "[0.87, 0.63-1.21]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Linked but not prescribed PrEP",
                        "HIV infection number": "36",
                        "Total number of individuals": "3013",
                        "total follow-up (person-years)": "4119",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[0.87, (0.63-1.21)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "HIV Incidence Rate Estimates",
                        "PrEP status": "Prescribed PrEP but did not initiate",
                        "HIV infections": "13",
                        "total No. of individuals": "811",
                        "total follow-up": "1226 person-years"
                    },
                    "measures": "[incidence, 95% CI]",
                    "outcomes": "[1.06, 0.62-1.83]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Prescribed PrEP but did not initiate",
                        "HIV infection number": "11",
                        "Total number of individuals": "811",
                        "total follow-up (person-years)": "1226",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[1.06, (0.62-1.83)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "HIV Incidence Rate Estimates",
                        "PrEP status": "Discontinued but reinitiated PrEP",
                        "HIV infections": "4",
                        "total No. of individuals": "1082",
                        "total follow-up": "1420 person-years"
                    },
                    "measures": "[incidence, 95% CI]",
                    "outcomes": "[0.28, 0.11-0.75]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Discontinued but reinitiated PrEP",
                        "HIV infection number": "4",
                        "Total number of individuals": "1082",
                        "total follow-up (person-years)": "1420",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[0.28, (0.11-0.75)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "HIV Incidence Rate Estimates",
                        "PrEP status": "Discontinued and did not reinitiate PrEP",
                        "HIV infections": "38",
                        "total No. of individuals": "2108",
                        "total follow-up": "2973 person-years"
                    },
                    "measures": "[incidence, 95% CI]",
                    "outcomes": "[1.28, 0.93-1.76]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Discontinued and did not reinitiate PrEP",
                        "HIV infection number": "38",
                        "Total number of individuals": "2108",
                        "total follow-up (person-years)": "2973",
                        "incidence": "per 100 person-years"
                    },
                    "measures": "[incidence rate, 95% CI]",
                    "outcomes": "[1.28, (0.93-1.76)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study": "HIV Incidence Rate Estimates",
                        "PrEP status": "Persistent on PrEP",
                        "definition": "individuals who initiated and remained on PrEP throughout follow-up",
                        "HIV infections": "0",
                        "total No. of individuals": "5367",
                        "total follow-up": "9139 person-years"
                    },
                    "measures": "[incidence, 95% CI]",
                    "outcomes": "[0.00, 0.00-0.04]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "HIV Incidence Rate Estimates",
                        "group": "Persistent on PrEP",
                        "HIV infection number": "0",
                        "Total number of individuals": "5367",
                        "total follow-up(person-years)": "9139",
                        "incidence": "per 100 person-years",
                        "definition": "Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up",
                        "confidence interval": "One-sided 97.5% upper CI"
                    },
                    "measures": "[incidence rate, 97.5% CI]",
                    "outcomes": "[0.00, (0.00-0.04)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 6,
        "total_ground_truth_claims": 6,
        "number_of_matches": 6
    },
    "PMC8748440_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "ISG15",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.29 (0.11\u20130.81), 0.0091]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "ISG15",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.29, 0.11\u20130.81 0.0091]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI6",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.18 (0.037\u20130.86), 0.014]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI6",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.18, 0.037\u20130.86, 0.014]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI44L",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.55 (0.27\u20131.1), 0.083]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI44L",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.55, 0.27\u20131.1, 0.083]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI44",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.23 (0.047\u20131.2), 0.045]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFI44",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.23, 0.047\u20131.2, 0.045]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFIT1",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.37 (0.12\u20131.1), 0.054]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "IFIT1",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.37, 0.12\u20131.1, 0.054]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "OAS3",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.52 (0.22\u20131.3), 0.15]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "OAS3",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.52, 0.22\u20131.3, 0.15]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "XAF1",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.3 (0.1\u20130.92), 0.027]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "XAF1",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.3, 0.1\u20130.92, 0.027]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "TRIM25",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.074 (0.0068\u20130.8), 0.023]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "TRIM25",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.074, 0.0068\u20130.8, 0.023]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "CMPK2",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.23 (0.037\u20131.5), 0.074]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "CMPK2",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.23, 0.037\u20131.5, 0.074]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "RSAD2",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.2 (0.041\u20130.99), 0.032]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "RSAD2",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.2, 0.041\u20130.99, 0.032]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "EIF2AK2",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.54 (0.12\u20132.4), 0.42]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "EIF2AK2",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.54, 0.12\u20132.4, 0.42]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "USP18",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.23 (0.062\u20130.84), 0.022]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "USP18",
                        "module": "salmon Module 1",
                        "selection criteria": "p < 0.05"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.23, 0.062\u20130.84, 0.022]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "HERC6",
                        "technique": "Cox regression",
                        "statistical representation": "HR (95% CI for HR)",
                        "statistical significance": "p value"
                    },
                    "measures": "[hazard ratio, p value]",
                    "outcomes": "[0.16 (0.019\u20131.3), 0.057]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Univariable Cox regression for individual hub genes",
                        "gene": "HERC6",
                        "module": "salmon Module 1"
                    },
                    "measures": "[HR, 95% CI, p value]",
                    "outcomes": "[0.16, 0.019\u20131.3, 0.057]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 13,
        "total_ground_truth_claims": 13,
        "number_of_matches": 13
    },
    "PMC7615197_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "126/257",
                        "hazard ratio": "0.85",
                        "confidence interval": "0.66-1.10",
                        "P value": "0.22",
                        "test for proportional hazards": "0.36",
                        "P-value for heterogeneity": ""
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.85, 0.22]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Intention-to-treat population",
                        "Deaths (Dexamethasone)": "116/263",
                        "Deaths (Placebo)": "126/257",
                        "Method": "Cox proportional hazards model",
                        "Test for proportional hazards": "0.36"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value]",
                    "outcomes": "[0.85, 0.66-1.10, 0.22]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "I",
                        "Deaths (Dexamethasone)": "22/99",
                        "Deaths (Placebo)": "28/97",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.41-1.25, 0.24, 0.15, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "II",
                        "Deaths (Dexamethasone)": "60/125",
                        "Deaths (Placebo)": "68/126",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.82, 0.58-1.16, 0.27, 0.30, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Intention-to-treat population",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "MRC grade": "Modified MRC grade",
                        "P-value for heterogeneity": "0.63"
                    },
                    "measures": "[]",
                    "outcomes": "[]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade I",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "28/97",
                        "hazard ratio": "0.72",
                        "confidence interval": "0.41-1.25",
                        "P value": "0.24",
                        "test for proportional hazards": "0.15"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.72, 0.24]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "I",
                        "Deaths (Dexamethasone)": "22/99",
                        "Deaths (Placebo)": "28/97",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.41-1.25, 0.24, 0.15, 0.63]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "II",
                        "Deaths (Dexamethasone)": "60/125",
                        "Deaths (Placebo)": "68/126",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.82, 0.58-1.16, 0.27, 0.30, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade II",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "68/126",
                        "hazard ratio": "0.82",
                        "confidence interval": "0.58-1.16",
                        "P value": "0.27",
                        "test for proportional hazards": "0.57"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[0.82, 0.27]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "II",
                        "Deaths (Dexamethasone)": "60/125",
                        "Deaths (Placebo)": "68/126",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.82, 0.58-1.16, 0.27, 0.30, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Modified MRC grade",
                        "Grade": "III",
                        "Deaths (Dexamethasone)": "34/39",
                        "Deaths (Placebo)": "30/34",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.03, 0.63-1.69, 0.90, 0.92, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Definite TBM",
                        "Deaths (Dexamethasone)": "48/108",
                        "Deaths (Placebo)": "49/104",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valu, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.90, 0.61-1.35, 0.62, 0.54, 0.63]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Probable TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.91, 0.64-1.30, 0.61, 0.17, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Diagnostic category",
                        "Category": "Possible TBM",
                        "Deaths (Dexamethasone)": "61/129",
                        "Deaths (Placebo)": "61/124",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.34, 0.66-1.63, 0.04, 0.08, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "TT",
                        "Deaths (Dexamethasone)": "12/25",
                        "Deaths (Placebo)": "11/26",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.06, 0.47-2.41, 0.88,0.17, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CT",
                        "Deaths (Dexamethasone)": "49/117",
                        "Deaths (Placebo)": "51/114",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.72, 0.49-1.05, 0.09, 0.25, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Leukotriene A4 hydrolase genotype",
                        "genotype": "CC",
                        "Deaths (Dexamethasone)": "38/84",
                        "Deaths (Placebo)": "36/80",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.04, 0.66-1.63, 0.88, 0.64, 0.40]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "MDR or rifampin mono-resistant",
                        "Deaths (Dexamethasone)": "7/10",
                        "Deaths (Placebo)": "5/6",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.66, 0.21-2.11, 0.48, 0.92, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "Isoniazid-resistant non-MDR",
                        "Deaths (Dexamethasone)": "6/14",
                        "Deaths (Placebo)": "13/20",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.56, 0.21-1.49, 0.25, 0.76, 0.37]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Anti-tuberculosis drug resistance",
                        "Drug resistance": "No or other resistance",
                        "Deaths (Dexamethasone)": "22/52",
                        "Deaths (Placebo)": "13/45",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.58, 0.79-3.13, 0.19, 0.37, 0.15]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "ART naive",
                        "Deaths (Dexamethasone)": "64/133",
                        "Deaths (Placebo)": "64/122",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.85, 0.60-1.21, 0.37, 0.20, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": ">3 months of ART",
                        "Deaths (Dexamethasone)": "20/46",
                        "Deaths (Placebo)": "26/58",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.54-1.72, 0.89, 0.83, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Art status on enrollment",
                        "Status": "Undetermined ART duration",
                        "Deaths (Dexamethasone)": "19/58",
                        "Deaths (Placebo)": "19/48",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.80, 0.42-1.51, 0.49, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "\u226450",
                        "Deaths (Dexamethasone)": "67/126",
                        "Deaths (Placebo)": "67/125",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P valueTest for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.96, 0.69-1.35, 0.87, 0.95, 0.91]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "51-100",
                        "Deaths (Dexamethasone)": "12/45",
                        "Deaths (Placebo)": "19/44",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.52, 0.23-1.06, 0.07, 0.22, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": "101-200",
                        "Deaths (Dexamethasone)": "14/36",
                        "Deaths (Placebo)": "13/35",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[1.24, 0.49-3.22, 0.65, 0.11, 0.41]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Analysis of primary outcome and pre-specified sub-groups in the intention-to-treat population",
                        "population": "Modified MRC grade: Grade III",
                        "treatment": "Dexamethasone",
                        "control": "Placebo",
                        "number of deaths": "30/34",
                        "hazard ratio": "1.11",
                        "confidence interval": "0.70-1.77",
                        "P value": "0.65",
                        "test for proportional hazards": "0.89"
                    },
                    "measures": "[hazard ratio, P value]",
                    "outcomes": "[1.11, 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Subgroup": "Enrolment CD4 count (per mm3)",
                        "CD4 count": ">200",
                        "Deaths (Dexamethasone)": "11/37",
                        "Deaths (Placebo)": "15/36",
                        "Method": "Subgroup Cox model"
                    },
                    "measures": "[Hazard Ratio, 95% CI, P value, Test for proportional hazards, P-value for heterogeneity]",
                    "outcomes": "[0.70, 0.32-1.52, 0.36, 0.20, 0.41]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 5,
        "total_ground_truth_claims": 20,
        "number_of_matches": 2
    },
    "PMC9008168_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                        "HIV status": "without HIV",
                        "ART status": "none",
                        "incidence rate type": "unadjusted",
                        "unit": "cases/1000 PY",
                        "statistical representation": "95% CI"
                    },
                    "measures": "[unadjusted incidence rate, HR]",
                    "outcomes": "[69.8, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                        "HIV status": "without HIV",
                        "ART status": "none",
                        "incidence rate type": "unadjusted",
                        "unit": "cases/1000 PY",
                        "statistical representation": "95% CI"
                    },
                    "measures": "[unadjusted incidence rate, HR]",
                    "outcomes": "[69.8, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                        "HIV status": "without HIV",
                        "ART status": "none",
                        "incidence rate type": "unadjusted",
                        "unit": "cases/1000 PY",
                        "statistical representation": "95% CI"
                    },
                    "measures": "[unadjusted incidence rate, HR]",
                    "outcomes": "[69.8, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                        "HIV status": "without HIV",
                        "ART status": "none",
                        "incidence rate type": "unadjusted",
                        "unit": "cases/1000 PY",
                        "statistical representation": "95% CI"
                    },
                    "measures": "[unadjusted incidence rate, HR]",
                    "outcomes": "[69.8, 1.00]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "People without HIV",
                        "Person-time": "937.23",
                        "Failures": "65",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[69.80, (54.74\u201389.01)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                        "HIV status": "with HIV",
                        "ART status": "non-TLD ART",
                        "incidence rate type": "unadjusted",
                        "unit": "cases/1000 PY",
                        "statistical representation": "95% CI"
                    },
                    "measures": "[unadjusted incidence rate, HR]",
                    "outcomes": "[77.1, 1.13]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on non-TLD ART",
                        "Person-time": "5069.11",
                        "Failures": "391",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[77.13, (69.85\u201385.17)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                        "HIV status": "with HIV",
                        "ART status": "TLD",
                        "incidence rate type": "unadjusted",
                        "unit": "cases/1000 PY",
                        "statistical representation": "95% CI"
                    },
                    "measures": "[unadjusted incidence rate, HR]",
                    "outcomes": "[73.3, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                        "HIV status": "with HIV",
                        "ART status": "TLD",
                        "incidence rate type": "unadjusted",
                        "unit": "cases/1000 PY",
                        "statistical representation": "95% CI"
                    },
                    "measures": "[unadjusted incidence rate, HR]",
                    "outcomes": "[73.3, 1.77]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH on TLD",
                        "Person-time": "559.35",
                        "Failures": "41",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[73.30, (53.97\u201399.55)]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "incidence rates and hazard ratios of BMI \u226525 kg/m\u00b2",
                        "HIV status": "with HIV",
                        "ART status": "ART na\u00efve",
                        "incidence rate type": "unadjusted",
                        "unit": "cases/1000 PY",
                        "statistical representation": "95% CI"
                    },
                    "measures": "[unadjusted incidence rate, HR]",
                    "outcomes": "[37.7, 0.43]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Group": "PLWH, ART na\u00efve",
                        "Person-time": "503.77",
                        "Failures": "19",
                        "Unadjusted incidence rate": "BMI \u226525 kg/m2"
                    },
                    "measures": "[Incidence rate per 100 person-years, (95% CI)]",
                    "outcomes": "[37.71, (24.06\u201359.13)]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 4,
        "total_ground_truth_claims": 4,
        "number_of_matches": 4
    },
    "PMC7644038_3": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Depression",
                        "HIV Prevalence": "24.3%",
                        "No HIV Prevalence": "6.2%",
                        "Percent Difference": "291.9%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[2.29, 2.22-2.35]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Chronic kidney disease",
                        "HIV Prevalence": "46.2%",
                        "No HIV Prevalence": "18.9%",
                        "Percent Difference": "144.4%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.92, 1.88-1.97]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "COPD",
                        "HIV Prevalence": "28.3%",
                        "No HIV Prevalence": "4.1%",
                        "Percent Difference": "590.2%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.52, 1.47-1.57]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Osteoporosis",
                        "HIV Prevalence": "14.6%",
                        "No HIV Prevalence": "3.4%",
                        "Percent Difference": "329.4%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[2.17, 2.06-2.29]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Colorectal cancer",
                        "HIV Prevalence": "3.8%",
                        "No HIV Prevalence": "1.3%",
                        "Percent Difference": "192.3%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.85, 1.70-2.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Lung cancer",
                        "HIV Prevalence": "26.8%",
                        "No HIV Prevalence": "7.7%",
                        "Percent Difference": "248.1%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.38, 1.25-1.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Hypertension",
                        "HIV Prevalence": "1.4%",
                        "No HIV Prevalence": "0.3%",
                        "Percent Difference": "366.7%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.31, 1.28-1.33]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Ischemic heart disease",
                        "HIV Prevalence": "1.3%",
                        "No HIV Prevalence": "0.3%",
                        "Percent Difference": "333.3%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.31, 1.28-1.34]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Diabetes",
                        "HIV Prevalence": "29.8%",
                        "No HIV Prevalence": "10.4%",
                        "Percent Difference": "186.5%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.06, 1.04-1.09]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Chronic hepatitis",
                        "HIV Prevalence": "13.1%",
                        "No HIV Prevalence": "0.2%",
                        "Percent Difference": "6450.0%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[12.70, 11.86-13.59]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[6.2%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "End-stage liver disease",
                        "HIV Prevalence": "2.7%",
                        "No HIV Prevalence": "0.1%",
                        "Percent Difference": "2600.0%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[4.51, 4.08-4.98]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Depression",
                        "HIV Prevalence": "24.3%",
                        "No HIV Prevalence": "6.2%",
                        "Percent Difference": "291.9%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[2.29, 2.22-2.35]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Chronic kidney disease",
                        "HIV Prevalence": "46.2%",
                        "No HIV Prevalence": "18.9%",
                        "Percent Difference": "144.4%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.92, 1.88-1.97]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "COPD",
                        "HIV Prevalence": "28.3%",
                        "No HIV Prevalence": "4.1%",
                        "Percent Difference": "590.2%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.52, 1.47-1.57]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Osteoporosis",
                        "HIV Prevalence": "14.6%",
                        "No HIV Prevalence": "3.4%",
                        "Percent Difference": "329.4%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[2.17, 2.06-2.29]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Colorectal cancer",
                        "HIV Prevalence": "3.8%",
                        "No HIV Prevalence": "1.3%",
                        "Percent Difference": "192.3%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.85, 1.70-2.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Lung cancer",
                        "HIV Prevalence": "26.8%",
                        "No HIV Prevalence": "7.7%",
                        "Percent Difference": "248.1%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.38, 1.25-1.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Hypertension",
                        "HIV Prevalence": "1.4%",
                        "No HIV Prevalence": "0.3%",
                        "Percent Difference": "366.7%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.31, 1.28-1.33]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Ischemic heart disease",
                        "HIV Prevalence": "1.3%",
                        "No HIV Prevalence": "0.3%",
                        "Percent Difference": "333.3%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.31, 1.28-1.34]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Diabetes",
                        "HIV Prevalence": "29.8%",
                        "No HIV Prevalence": "10.4%",
                        "Percent Difference": "186.5%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.06, 1.04-1.09]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Chronic hepatitis",
                        "HIV Prevalence": "13.1%",
                        "No HIV Prevalence": "0.2%",
                        "Percent Difference": "6450.0%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[12.70, 11.86-13.59]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Depression",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[291.9%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "End-stage liver disease",
                        "HIV Prevalence": "2.7%",
                        "No HIV Prevalence": "0.1%",
                        "Percent Difference": "2600.0%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[4.51, 4.08-4.98]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Depression",
                        "HIV Prevalence": "24.3%",
                        "No HIV Prevalence": "6.2%",
                        "Percent Difference": "291.9%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[2.29, 2.22-2.35]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Chronic kidney disease",
                        "HIV Prevalence": "46.2%",
                        "No HIV Prevalence": "18.9%",
                        "Percent Difference": "144.4%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.92, 1.88-1.97]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "COPD",
                        "HIV Prevalence": "28.3%",
                        "No HIV Prevalence": "4.1%",
                        "Percent Difference": "590.2%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.52, 1.47-1.57]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Osteoporosis",
                        "HIV Prevalence": "14.6%",
                        "No HIV Prevalence": "3.4%",
                        "Percent Difference": "329.4%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[2.17, 2.06-2.29]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Colorectal cancer",
                        "HIV Prevalence": "3.8%",
                        "No HIV Prevalence": "1.3%",
                        "Percent Difference": "192.3%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.85, 1.70-2.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Lung cancer",
                        "HIV Prevalence": "26.8%",
                        "No HIV Prevalence": "7.7%",
                        "Percent Difference": "248.1%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.38, 1.25-1.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Hypertension",
                        "HIV Prevalence": "1.4%",
                        "No HIV Prevalence": "0.3%",
                        "Percent Difference": "366.7%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.31, 1.28-1.33]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Ischemic heart disease",
                        "HIV Prevalence": "1.3%",
                        "No HIV Prevalence": "0.3%",
                        "Percent Difference": "333.3%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.31, 1.28-1.34]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Diabetes",
                        "HIV Prevalence": "29.8%",
                        "No HIV Prevalence": "10.4%",
                        "Percent Difference": "186.5%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.06, 1.04-1.09]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Chronic hepatitis",
                        "HIV Prevalence": "13.1%",
                        "No HIV Prevalence": "0.2%",
                        "Percent Difference": "6450.0%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[12.70, 11.86-13.59]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[prevalence]",
                    "outcomes": "[18.9%]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "End-stage liver disease",
                        "HIV Prevalence": "2.7%",
                        "No HIV Prevalence": "0.1%",
                        "Percent Difference": "2600.0%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[4.51, 4.08-4.98]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Depression",
                        "HIV Prevalence": "24.3%",
                        "No HIV Prevalence": "6.2%",
                        "Percent Difference": "291.9%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[2.29, 2.22-2.35]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Chronic kidney disease",
                        "HIV Prevalence": "46.2%",
                        "No HIV Prevalence": "18.9%",
                        "Percent Difference": "144.4%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.92, 1.88-1.97]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "COPD",
                        "HIV Prevalence": "28.3%",
                        "No HIV Prevalence": "4.1%",
                        "Percent Difference": "590.2%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.52, 1.47-1.57]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Osteoporosis",
                        "HIV Prevalence": "14.6%",
                        "No HIV Prevalence": "3.4%",
                        "Percent Difference": "329.4%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[2.17, 2.06-2.29]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Colorectal cancer",
                        "HIV Prevalence": "3.8%",
                        "No HIV Prevalence": "1.3%",
                        "Percent Difference": "192.3%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.85, 1.70-2.03]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Lung cancer",
                        "HIV Prevalence": "26.8%",
                        "No HIV Prevalence": "7.7%",
                        "Percent Difference": "248.1%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.38, 1.25-1.53]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Hypertension",
                        "HIV Prevalence": "1.4%",
                        "No HIV Prevalence": "0.3%",
                        "Percent Difference": "366.7%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.31, 1.28-1.33]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Ischemic heart disease",
                        "HIV Prevalence": "1.3%",
                        "No HIV Prevalence": "0.3%",
                        "Percent Difference": "333.3%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.31, 1.28-1.34]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Diabetes",
                        "HIV Prevalence": "29.8%",
                        "No HIV Prevalence": "10.4%",
                        "Percent Difference": "186.5%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[1.06, 1.04-1.09]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "Chronic hepatitis",
                        "HIV Prevalence": "13.1%",
                        "No HIV Prevalence": "0.2%",
                        "Percent Difference": "6450.0%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[12.70, 11.86-13.59]"
                },
                "match": "no"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "analysis": "Prevalence of health outcomes",
                        "study population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                        "study design": "unadjusted",
                        "health outcome": "Chronic kidney disease",
                        "HIV status": "HIV vs No HIV",
                        "age": "65",
                        "year": "2011\u20132016"
                    },
                    "measures": "[percent difference]",
                    "outcomes": "[144.4%***]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "Health Outcome": "End-stage liver disease",
                        "HIV Prevalence": "2.7%",
                        "No HIV Prevalence": "0.1%",
                        "Percent Difference": "2600.0%",
                        "Method": "Logistic regression model (2016 data)"
                    },
                    "measures": "[Odds Ratio, 95% CI]",
                    "outcomes": "[4.51, 4.08-4.98]"
                },
                "match": "no"
            }
        ],
        "total_extracted_claims": 4,
        "total_ground_truth_claims": 11,
        "number_of_matches": 0
    },
    "PMC6033411_2": {
        "matches": [
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total number": "69",
                        "percentage": "34.5%",
                        "clustered": "22",
                        "clustered percentage": "37.3%",
                        "odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "15 and younger",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Age (years)",
                        "age group": "16",
                        "total number": "46",
                        "percentage": "23%",
                        "clustered": "13",
                        "clustered percentage": "22%",
                        "odds ratio": "0.84 (0.36\u20131.89)",
                        "P-value": "0.67"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "16",
                        "total participants": "46 (23%)",
                        "clustered participants": "13 (22%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Age (years)",
                        "age group": "17+",
                        "total number": "85",
                        "percentage": "42.5%",
                        "clustered": "24",
                        "clustered percentage": "40.7%",
                        "odds ratio": "0.87 (0.43\u20131.76)",
                        "P-value": "0.69"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Age (years)",
                        "age group": "17+",
                        "total participants": "85 (42.5%)",
                        "clustered participants": "24 (40.7%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "School grade",
                        "school grade": "8\u20139",
                        "total number": "90",
                        "percentage": "45%",
                        "clustered": "30",
                        "clustered percentage": "50.8%",
                        "odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "8\u20139",
                        "total participants": "90 (45%)",
                        "clustered participants": "30 (50.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "School grade",
                        "school grade": "10\u201312",
                        "total number": "110",
                        "percentage": "55%",
                        "clustered": "29",
                        "clustered percentage": "49.2%",
                        "odds ratio": "0.8 (0.43\u20131.52)",
                        "P-value": "0.5"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "School grade",
                        "grade group": "10\u201312",
                        "total participants": "110 (55%)",
                        "clustered participants": "29 (49.2%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Household income (R)",
                        "household income": "<999",
                        "total number": "61",
                        "percentage": "30.5%",
                        "clustered": "22",
                        "clustered percentage": "37.3%",
                        "odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "<999",
                        "total participants": "61 (30.5%)",
                        "clustered participants": "22 (37.3%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Household income (R)",
                        "household income": "10,000\u201399,000",
                        "total number": "112",
                        "percentage": "56%",
                        "clustered": "27",
                        "clustered percentage": "45.8%",
                        "odds ratio": "0.56 (0.29\u20131.11)",
                        "P-value": "0.1"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": "10,000\u201399,000",
                        "total participants": "112 (56%)",
                        "clustered participants": "27 (45.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Household income (R)",
                        "household income": ">100,000",
                        "total number": "27",
                        "percentage": "12.5%",
                        "clustered": "10",
                        "clustered percentage": "16.9%",
                        "odds ratio": "1.04 (0.39\u20132.65)",
                        "P-value": "0.93"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Household income (R)",
                        "income group": ">100,000",
                        "total participants": "27 (12.5%)",
                        "clustered participants": "10 (16.9%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 cell count": ">500",
                        "total number": "92",
                        "percentage": "46%",
                        "clustered": "30",
                        "clustered percentage": "50.9%",
                        "odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": ">500",
                        "total participants": "92 (46%)",
                        "clustered participants": "30 (50.9%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 cell count": "\u2264500",
                        "total number": "75",
                        "percentage": "37.5%",
                        "clustered": "19",
                        "clustered percentage": "32.2%",
                        "odds ratio": "0.70 (0.35\u20131.37)",
                        "P-value": "0.31"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264500",
                        "total participants": "75 (37.5%)",
                        "clustered participants": "19 (32.2%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 cell count": "\u2264250",
                        "total number": "15",
                        "percentage": "7.5%",
                        "clustered": "4",
                        "clustered percentage": "6.8%",
                        "odds ratio": "0.75 (0.2\u20132.4)",
                        "P-value": "0.65"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "CD4 cell count, cells/mm\u00b3",
                        "CD4 group": "\u2264250",
                        "total participants": "15 (7.5%)",
                        "clustered participants": "4 (6.8%)",
                        "footnote": "CD4 cell count data was not available for 18 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Major drug resistance mutation",
                        "major drug resistance mutation": "No",
                        "total number": "180",
                        "percentage": "90%",
                        "clustered": "55",
                        "clustered percentage": "93.2%",
                        "odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "No",
                        "total participants": "180 (90%)",
                        "clustered participants": "55 (93.2)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Major drug resistance mutation",
                        "major drug resistance mutation": "Yes",
                        "total number": "20",
                        "percentage": "10%",
                        "clustered": "4",
                        "clustered percentage": "6.8%",
                        "odds ratio": "0.57 (0.16\u20131.63)",
                        "P-value": "0.33"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Major drug resistance mutation",
                        "mutation status": "Yes",
                        "total participants": "20 (10%)",
                        "clustered participants": "4 (6.8%)"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "HSV-2 infection",
                        "HSV-2 infection": "No",
                        "total number": "90",
                        "percentage": "45%",
                        "clustered": "25",
                        "clustered percentage": "42.4%",
                        "odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "No",
                        "total participants": "90 (45%)",
                        "clustered participants": "25 (42.4%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "HSV-2 infection",
                        "HSV-2 infection": "Yes",
                        "total number": "69",
                        "percentage": "34.5%",
                        "clustered": "23",
                        "clustered percentage": "39%",
                        "odds ratio": "1.3 (0.65\u20132.57)",
                        "P-value": "0.45"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "HSV-2 infection",
                        "infection status": "Yes",
                        "total participants": "69 (34.5%)",
                        "clustered participants": "23 (39%)",
                        "footnote": "HSV-2 infection status was not available for 41 women"
                    },
                    "measures": "[odds ratio, 95% CI, P-value]",
                    "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Ever pregnant",
                        "ever pregnant": "No",
                        "total number": "122",
                        "percentage": "61%",
                        "clustered": "37",
                        "clustered percentage": "62.7%",
                        "odds ratio": "1.0 (ref)",
                        "P-value": "\u2026"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "No",
                        "total participants": "122 (61%)",
                        "clustered participants": "37 (62.7%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.0 (ref), \u2026]"
                },
                "match": "yes"
            },
            {
                "Extracted_claim": {
                    "subject": {
                        "study type": "HIV-infected study",
                        "number of participants": "200",
                        "characteristic": "Ever pregnant",
                        "ever pregnant": "Yes",
                        "total number": "49",
                        "percentage": "24.5%",
                        "clustered": "15",
                        "clustered percentage": "25.4%",
                        "odds ratio": "1.01 (0.48\u20132.06)",
                        "P-value": "0.971"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
                },
                "Ground_truth_claim": {
                    "subject": {
                        "analysis": "Associations between demographic and epidemiological characteristics of HIV-infected study participants and phylogenetic clustering",
                        "threshold": "4.5% genetic distance",
                        "characteristic": "Ever pregnant",
                        "pregnancy status": "Yes",
                        "total participants": "49 (24.5%)",
                        "clustered participants": "15 (25.4%)",
                        "footnote": "Pregnancy history was not available for 29 women"
                    },
                    "measures": "[odds ratio, P-value]",
                    "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
                },
                "match": "yes"
            }
        ],
        "total_extracted_claims": 17,
        "total_ground_truth_claims": 17,
        "number_of_matches": 17
    }
}